Previous research has suggested that up to a quarter of patients who receive the common chemotherapy drug doxorubicin are at risk of developing heart failure later in life. Exactly how that heart damage is done remains unclear.
In this study, scientists identified a protein called heat shock factor-1 (HSF-1) as a likely source of chemotherapy-related heart damage in mice and cell cultures. Heat shock factor-1 is known to be induced by stress - in this case, the chemotherapy treatment itself.
"We have found that a simple stress-related factor could be aggravating chemotherapy's effect on the heart," said Govindasamy Ilangovan, associate professor of internal medicine at Ohio State University and senior author of the study. "The results are leading us toward the idea that any additional stress could hurt the heart more than what chemotherapy itself can do."
The researchers gave doxorubicin to two sets of mice - normal animals and mice that were genetically altered so they could not produce HSF-1. Mice without HSF-1 had healthier hearts and lived longer after the chemotherapy treatment than did normal mice.
A closer examination on the cellular level suggested that when HSF-1 is blocked in the heart, this condition allows for the activation of a gene that produces a protein to pump the chemo medicine out of heart muscle cells, preventing these cells from dying.
Ilangovan and colleagues are working to design drugs that could selectively inhibit HSF-1 in the heart as a potential additional therapy for cancer patients undergoing chemo treatment.
The research appears this week in the Proceedings of the National Academy of Sciences Online Early Edition.
Chemotherapy targets cancer cells, but it also can kill many other kinds of cells in various organs. In most cases, Ilangovan explained, organs can regenerate their cells after this damage has occurred. But cardiomyocytes, or heart muscle cells, cannot be regenerated. The loss of muscle can lead to a disorder known as dilated cardiomyopathy, which reduces the heart's pumping action and leads to heart failure.
"This work arose from that background. We are trying to identify a factor that can be targeted to prevent the cardiomyopathy," said Ilangovan, an investigator in Ohio State's Davis Heart & Lung Research Institute.
Previous research had already shown that doxorubicin leads to activation of HSF-1 in the heart. The Ohio State researchers ran a number of experiments in animals and cell cultures to establish the relationship after chemo treatment between heat shock factor-1 and the gene that helps the heart, called multidrug-resistance-1 or MDR1.
In analyses using heart muscle cells from mice with and without activation of HSF-1, the researchers observed more activation of the MDR1 gene in cells lacking the HSF-1 protein compared to normal mouse heart cells. In addition, they demonstrated that the MDR1 gene prompted production of a protein on these heart cells' surface that actually pumped doxorubicin away from the cells.
"This was an exciting finding. When we knock out the protein, not only is the cell death pathway prevented, but it also induces a multidrug-resistant gene, which pumps the drug away from the cells," Ilangovan said. "So when HSF-1 gets activated by chemo, that leads to cardiomyocyte death. But if we knock it out, that gene comes and protects the heart."
The researchers discovered that interplay in the heart cells between HSF-1 and another protein, NF-kB, could be traced to production of the protective gene.
"They're sort of antagonizing each other. If HSF-1 is lower, the other protein becomes dominant. They compete for the same binding site, and when we knock out HSF-1, NF-kB can go freely bind and activate the MDR1 gene," Ilangovan said. That also means that when HSF-1 is present, it inhibits NF-kB and in turn prevents the protective gene from being activated.
Mice also survived longer after a doxorubicin treatment if they did not produce HSF-1, and images of their hearts showed that chemo-related damage to the heart was reduced in the genetically altered mice compared to normal mice.
The researchers also tested breast cancer cells to be sure that brief silencing of the HSF-1 protein before chemotherapy would not induce the multidrug-resistant gene in those cells, which could be a deadly turn of events.
Proper timing of HSF-1 inhibition and limiting this inhibition to the heart are important steps in designing drugs to target it, Ilangovan said. Multiple studies of this protein have suggested that it can have both beneficial and harmful effects in the body. Researchers appear to be reaching consensus that the timing of its activation helps determine which effect it will have - if it is activated before an injury or other damaging event, HSF-1 can be protective. After an injury - in this case, doxorubicin treatment - the protein is more commonly found to be harmful.
"I foresee that perhaps a patient would take a drug to silence HSF-1 in the heart one or two days before chemotherapy. So until the chemo is cleared out, the protein would be in the knock-down stage and no damage to the heart would occur," Ilangovan said.
This work is supported by grants from the National Institutes of Health.
Co-authors of this study include Karthikeyan Krishnamurthy, Kaushik Vedam and Ragu Kanagasabai of the Department of Internal Medicine and Lawrence Druhan of the Department of Anesthesiology, all at Ohio State.
Contact: Govindasamy Ilangovan, (614) 292-9064; firstname.lastname@example.org
Written by Emily Caldwell, (614) 292-8310; email@example.com
Govindasamy Ilangovan | EurekAlert!
Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University
New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg
Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.
The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
23.03.2018 | Event News
19.03.2018 | Event News
16.03.2018 | Event News
23.03.2018 | Materials Sciences
23.03.2018 | Agricultural and Forestry Science
23.03.2018 | Physics and Astronomy